1
|
Borroto-Escuela D, Serrano-Castro P, Sánchez-Pérez JA, Barbancho-Fernández MA, Fuxe K, Narváez M. Enhanced neuronal survival and BDNF elevation via long-term co-activation of galanin 2 (GALR2) and neuropeptide Y1 receptors (NPY1R): potential therapeutic targets for major depressive disorder. Expert Opin Ther Targets 2024; 28:295-308. [PMID: 38622072 DOI: 10.1080/14728222.2024.2342517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2024] [Accepted: 04/05/2024] [Indexed: 04/17/2024]
Abstract
BACKGROUND Major Depressive Disorder (MDD) is a prevalent and debilitating condition, necessitating novel therapeutic strategies due to the limited efficacy and adverse effects of current treatments. We explored how galanin receptor 2 (GALR2) and Neuropeptide Y1 Receptor (NPYY1R) agonists, working together, can boost brain cell growth and increase antidepressant-like effects in rats. This suggests new ways to treat Major Depressive Disorder (MDD). RESEARCH DESIGN AND METHODS In a controlled laboratory setting, adult naive Sprague-Dawley rats were administered directly into the brain's ventricles, a method known as intracerebroventricular (ICV) administration, with GALR2 agonist (M1145), NPYY1R agonist, both, or in combination with a GALR2 antagonist (M871). Main outcome measures included long-term neuronal survival, differentiation, and behavioral. RESULTS Co-administration of M1145 and NPYY1R agonist significantly enhanced neuronal survival and maturation in the ventral dentate gyrus, with a notable increase in Brain-Derived Neurotrophic Factor (BDNF) expression. This neurogenic effect was associated with an antidepressant-like effect, an outcome partially reversed by M871. CONCLUSIONS GALR2 and NPYY1R agonists jointly promote hippocampal neurogenesis and exert antidepressant-like effects in rats without adverse outcomes, highlighting their therapeutic potential for MDD. The study's reliance on an animal model and intracerebroventricular delivery warrants further clinical exploration to confirm these promising results.
Collapse
MESH Headings
- Animals
- Depressive Disorder, Major/drug therapy
- Depressive Disorder, Major/physiopathology
- Receptor, Galanin, Type 2/metabolism
- Rats, Sprague-Dawley
- Rats
- Brain-Derived Neurotrophic Factor/metabolism
- Male
- Receptors, Neuropeptide Y/metabolism
- Receptors, Neuropeptide Y/antagonists & inhibitors
- Neurons/drug effects
- Neurons/metabolism
- Cell Survival/drug effects
- Antidepressive Agents/pharmacology
- Antidepressive Agents/administration & dosage
- Disease Models, Animal
- Peptides
- Receptors, Neuropeptide
- Receptors, G-Protein-Coupled
Collapse
Affiliation(s)
- Dasiel Borroto-Escuela
- Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
- Receptomics and Brain Disorders Lab, Edificio Lopez-Peñalver, Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Universidad de Málaga, Málaga, Spain
| | - Pedro Serrano-Castro
- Instituto de Investigación Biomédica de Málaga, NeuronLab, Facultad de Medicina, Universidad de Málaga, Málaga, Spain
- Instituto de Investigación Biomédica de Málaga, Unit of Neurology, Hospital Regional Universitario de Málaga, Málaga, Spain
- Vithas Málaga, Vithas Málaga, Grupo Hospitalario Vithas, Málaga, Spain
| | - Jose Andrés Sánchez-Pérez
- Instituto de Investigación Biomédica de Málaga, NeuronLab, Facultad de Medicina, Universidad de Málaga, Málaga, Spain
- Instituto de Investigación Biomédica de Málaga, Unit of Psychiatry, Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | | | - Kjell Fuxe
- Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Manuel Narváez
- Instituto de Investigación Biomédica de Málaga, NeuronLab, Facultad de Medicina, Universidad de Málaga, Málaga, Spain
- Instituto de Investigación Biomédica de Málaga, Unit of Neurology, Hospital Regional Universitario de Málaga, Málaga, Spain
- Vithas Málaga, Vithas Málaga, Grupo Hospitalario Vithas, Málaga, Spain
| |
Collapse
|
2
|
Gimeno-Ferrer F, Eitner A, Bauer R, Lehmenkühler A, Schaible HG, Richter F. Cortical spreading depolarization is a potential target for rat brain excitability modulation by Galanin. Exp Neurol 2023; 370:114569. [PMID: 37827229 DOI: 10.1016/j.expneurol.2023.114569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 08/24/2023] [Accepted: 10/09/2023] [Indexed: 10/14/2023]
Abstract
The inhibitory neuropeptide Galanin (Gal) has been shown to mediate anticonvulsion and neuroprotection. Here we investigated whether Gal affects cortical spreading depolarization (CSD). CSD is considered the pathophysiological neuronal mechanism of migraine aura, and a neuronal mechanism aggravating brain damage upon afflictions of the brain. Immunohistochemistry localized Gal and the Gal receptors 1-3 (GalR1-3) in native rat cortex and evaluated microglial morphology after exposure to Gal. In anesthetized rats, Gal was applied alone and together with the GalR antagonists M40, M871, or SNAP 37889 locally to the exposed cortex. The spontaneous electrocorticogram and CSDs evoked by remote KCl pressure microinjection were measured. In rat cortex, Gal was present in all neurons of all cortical layers, but not in astrocytes, microglia and vessels. GalR2 and GalR3 were expressed throughout all neurons, whereas GalR1 was preponderantly located at neurons in layers IV and V, but only in about half of the neurons. In susceptible rats, topical application of Gal on cortex decreased CSD amplitude, slowed CSD propagation velocity, and increased the threshold for KCl to ignite CSD. In some rats, washout of previously applied Gal induced periods of epileptiform patterns in the electrocorticogram. Blockade of GalR2 by M871 robustly prevented all Gal effects on CSD, whereas blockade of GalR1 or GalR3 was less effective. Although microglia did not express GalRs, topical application of Gal changed microglial morphology indicating microglial activation. This effect of Gal on microglia was prevented by blocking neuronal GalR2. In conclusion, Gal has the potential to ameliorate CSD thus reducing pathophysiological neuronal events caused by or associated with CSD.
Collapse
Affiliation(s)
- Fátima Gimeno-Ferrer
- Institute of Physiology 1/Neurophysiology, Jena University Hospital, Jena D-07740, Germany
| | - Annett Eitner
- Department of Trauma, Hand and Reconstructive Surgery, Experimental Trauma Surgery, Jena University Hospital, Jena D-07740, Germany
| | - Reinhard Bauer
- Institute of Molecular Cell Biology, CMB-Center for Molecular Biomedicine, Jena University Hospital, Jena D-07740, Germany
| | | | - Hans-Georg Schaible
- Institute of Physiology 1/Neurophysiology, Jena University Hospital, Jena D-07740, Germany
| | - Frank Richter
- Institute of Physiology 1/Neurophysiology, Jena University Hospital, Jena D-07740, Germany.
| |
Collapse
|
3
|
Neuroanatomical characterization of the G protein-coupled receptor activity evoked by galanin-related ligands. J Chem Neuroanat 2023; 128:102226. [PMID: 36566994 DOI: 10.1016/j.jchemneu.2022.102226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Revised: 12/21/2022] [Accepted: 12/21/2022] [Indexed: 12/24/2022]
Abstract
Galanin neuropeptide is distributed throughout the mammalian nervous system modulating a plethora of diverse physiological functions, including nociception, cognition and neuroendocrine regulation. The regulation of the galaninergic system is an interesting approach for the treatment of different diseases associated to those systems. Nevertheless, the pharmacological selectivity and activities of some galanin receptor (GalR) ligands are still in discussion and seem to depend on the dose, the receptor subtype and the second messengers to which they are coupled at different brain areas. The activity of different GalR ligands on Gi/o proteins, was evaluated by the guanosine 5'-(γ-[35S]thio)triphosphate ([35S]GTPγS) autoradiography in vitro assay applied to rat brain tissue slices in the presence of galanin, M15, M35, M40, gal(2-11) or galnon. The enhancement of the [35S]GTPγS binding induced by the chimerical peptides M15, M35 and M40 was similar to that produced by Gal in those brain areas showing the highest stimulations, such as dorsal part of the olfactory nucleus and ventral subiculum. In contrast to these peptides, using gal(2-11) no effect was measured on Gi/o protein coupling in areas of the rat brain with high GalR1 density such as posterior hypothalamic nucleus and amygdala, indicating low selectivity for GalR1 receptors. The effects evoked by the non-peptide ligand, galnon, were different from those induced by galanin, behaving as agonist or antagonist depending on the brain area, but the stimulations were always blocked by M35. Thus, the activity of most used GalR ligands on Gi/o protein mediated signalling is complex and depends on the brain area. More selective and potent GalR ligands are necessary to develop new treatments aimed to modulate the galaninergic system.
Collapse
|
4
|
Díaz-Sánchez E, López-Salas A, Mirchandani-Duque M, Alvarez-Contino JE, Sánchez-Pérez JA, Fuxe K, Borroto-Escuela DO, García-Casares N, Narváez M. Decreased medial prefrontal cortex activity related to impaired novel object preference task performance following GALR2 and Y1R agonists intranasal infusion. Biomed Pharmacother 2023; 161:114433. [PMID: 36848750 DOI: 10.1016/j.biopha.2023.114433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Revised: 02/10/2023] [Accepted: 02/20/2023] [Indexed: 02/27/2023] Open
Abstract
Different brain regions' interactions have been implicated in relevant neurological diseases, such as major depressive disorder (MDD), anxiety disorders, age-dependent cognitive decline, Alzheimer's disease (AD) and addiction. We aim to explore the role of the medial prefrontal cortex (mPFC) in the Neuropeptide Y (NPY) and Galanin (GAL) interaction since we have demonstrated specific NPY and GAL interactions in brain areas related to these brain diseases. We performed GALR2 and Y1R agonists intranasal infusion and analyzed the mPFC activation through c-Fos expression. To assess the associated cellular mechanism we studied the formation of Y1R-GALR2 heteroreceptor complexes with in situ proximity ligation assay (PLA) and the expression of the brain-derived neurotrophic factor (BDNF). Moreover, the functional outcome of the NPY and GAL interaction on the mPFC was evaluated in the novel object preference task. We demonstrated that the intranasal administration of both agonists decrease the medial prefrontal cortex activation as shown with the c-Fos expression. These effects were mediated by the decreased formation of Y1R-GALR2 heteroreceptor complexes without affecting the BDNF expression. The functional outcome of this interaction was related to an impaired performance on the novel object preference task. Our data may suggest the translational development of new heterobivalent agonist pharmacophores acting on Y1R-GALR2 heterocomplexes in the medial prefrontal cortex for the novel therapy on neurodegenerative and psychiatric diseases. DATA SHARING AND DATA ACCESSIBILITY: The data that support the findings of this study are openly available in Institutional repository of the University of Malaga (RIUMA) and from the corresponding author upon reasonable request.
Collapse
Affiliation(s)
- Estela Díaz-Sánchez
- Laboratorio NeuronLab. Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Universidad de Málaga, Malaga 29071, Spain; Vithas Málaga. Grupo Hospitalario Vithas, Málaga, Spain.
| | - Alexander López-Salas
- Laboratorio NeuronLab. Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Universidad de Málaga, Malaga 29071, Spain.
| | - Marina Mirchandani-Duque
- Laboratorio NeuronLab. Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Universidad de Málaga, Malaga 29071, Spain.
| | - Jose Erik Alvarez-Contino
- Laboratorio NeuronLab. Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Universidad de Málaga, Malaga 29071, Spain.
| | - Jose Andrés Sánchez-Pérez
- Instituto de Investigación Biomédica de Málaga, Unit of Psychiatry, Hospital Universitario Virgen de la Victoria, Spain.
| | - Kjell Fuxe
- Department of Neuroscience, Karolinska Institute, Stockholm 17177, Sweden.
| | - Dasiel O Borroto-Escuela
- Laboratorio NeuronLab. Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Universidad de Málaga, Malaga 29071, Spain; Department of Neuroscience, Karolinska Institute, Stockholm 17177, Sweden; Department of Biomolecular Science, Section of Physiology, University of Urbino, Urbino 61029, Italy.
| | - Natalia García-Casares
- Laboratorio NeuronLab. Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Universidad de Málaga, Malaga 29071, Spain.
| | - Manuel Narváez
- Laboratorio NeuronLab. Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Universidad de Málaga, Malaga 29071, Spain; Vithas Málaga. Grupo Hospitalario Vithas, Málaga, Spain; Department of Neuroscience, Karolinska Institute, Stockholm 17177, Sweden.
| |
Collapse
|
5
|
Alvarez‐Contino JE, Díaz‐Sánchez E, Mirchandani‐Duque M, Sánchez‐Pérez JA, Barbancho MA, López‐Salas A, García‐Casares N, Fuxe K, Borroto‐Escuela DO, Narváez M. GALR2 and Y1R agonists intranasal infusion enhanced adult ventral hippocampal neurogenesis and antidepressant-like effects involving BDNF actions. J Cell Physiol 2023; 238:459-474. [PMID: 36599082 PMCID: PMC10952952 DOI: 10.1002/jcp.30944] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2022] [Revised: 11/28/2022] [Accepted: 12/24/2022] [Indexed: 01/06/2023]
Abstract
Dysregulation of adult hippocampal neurogenesis is linked to major depressive disorder (MDD), with more than 300 million people diagnosed and worsened by the COVID-19 pandemic. Accumulating evidence for neuropeptide Y (NPY) and galanin (GAL) interaction was shown in various limbic system regions at molecular-, cellular-, and behavioral-specific levels. The purpose of the current work was to evaluate the proliferating role of GAL2 receptor (GALR2) and Y1R agonists interaction upon intranasal infusion in the ventral hippocampus. We studied their hippocampal proliferating actions using the proliferating cell nuclear antigen (PCNA) on neuroblasts or stem cells and the expression of the brain-derived neurothrophic factor (BDNF). Moreover, we studied the formation of Y1R-GALR2 heteroreceptor complexes and analyzed morphological changes in hippocampal neuronal cells. Finally, the functional outcome of the NPY and GAL interaction on the ventral hippocampus was evaluated in the forced swimming test. We demonstrated that the intranasal infusion of GALR2 and the Y1R agonists promotes neuroblasts proliferation in the dentate gyrus of the ventral hippocampus and the induction of the neurotrophic factor BDNF. These effects were mediated by the increased formation of Y1R-GALR2 heteroreceptor complexes, which may mediate the neurites outgrowth observed on neuronal hippocampal cells. Importantly, BDNF action was found necessary for the antidepressant-like effects after GALR2 and the Y1R agonists intranasal administration. Our data may suggest the translational development of new heterobivalent agonist pharmacophores acting on Y1R-GALR2 heterocomplexes in the ventral hippocampus for the novel therapy of MDD or depressive-affecting diseases.
Collapse
Affiliation(s)
- Jose Erik Alvarez‐Contino
- Laboratorio NeuronLab, Instituto de Investigación Biomédica de Málaga, Facultad de MedicinaUniversidad de MálagaMalagaSpain
| | - Estela Díaz‐Sánchez
- Laboratorio NeuronLab, Instituto de Investigación Biomédica de Málaga, Facultad de MedicinaUniversidad de MálagaMalagaSpain
- Grupo Hospitalario VithasVithas MálagaMálagaSpain
| | - Marina Mirchandani‐Duque
- Laboratorio NeuronLab, Instituto de Investigación Biomédica de Málaga, Facultad de MedicinaUniversidad de MálagaMalagaSpain
| | - Jose Andrés Sánchez‐Pérez
- Unit of Psychiatry, Instituto de Investigación Biomédica de MálagaHospital Universitario Virgen de la VictoriaMálagaSpain
| | - Miguel A. Barbancho
- Laboratorio NeuronLab, Instituto de Investigación Biomédica de Málaga, Facultad de MedicinaUniversidad de MálagaMalagaSpain
| | - Alexander López‐Salas
- Laboratorio NeuronLab, Instituto de Investigación Biomédica de Málaga, Facultad de MedicinaUniversidad de MálagaMalagaSpain
| | - Natalia García‐Casares
- Laboratorio NeuronLab, Instituto de Investigación Biomédica de Málaga, Facultad de MedicinaUniversidad de MálagaMalagaSpain
| | - Kjell Fuxe
- Department of NeuroscienceKarolinska InstituteStockholmSweden
| | - Dasiel O. Borroto‐Escuela
- Laboratorio NeuronLab, Instituto de Investigación Biomédica de Málaga, Facultad de MedicinaUniversidad de MálagaMalagaSpain
- Department of NeuroscienceKarolinska InstituteStockholmSweden
- Department of Biomolecular Science, Section of PhysiologyUniversity of UrbinoUrbinoItaly
| | - Manuel Narváez
- Laboratorio NeuronLab, Instituto de Investigación Biomédica de Málaga, Facultad de MedicinaUniversidad de MálagaMalagaSpain
- Grupo Hospitalario VithasVithas MálagaMálagaSpain
- Department of NeuroscienceKarolinska InstituteStockholmSweden
| |
Collapse
|
6
|
Exploring the role of neuropeptides in depression and anxiety. Prog Neuropsychopharmacol Biol Psychiatry 2022; 114:110478. [PMID: 34801611 DOI: 10.1016/j.pnpbp.2021.110478] [Citation(s) in RCA: 37] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Revised: 11/13/2021] [Accepted: 11/13/2021] [Indexed: 12/24/2022]
Abstract
Depression is one of the most prevalent forms of mental disorders and is the most common cause of disability in the Western world. Besides, the harmful effects of stress-related mood disorders on the patients themselves, they challenge the health care system with enormous social and economic impacts. Due to the high proportion of patients not responding to existing drugs, finding new treatment strategies has become an important topic in neurobiology, and there is much evidence that neuropeptides are not only involved in the physiology of stress but may also be clinically important. Based on preclinical trial data, new neuropharmaceutical candidates may target neuropeptides and their receptors and are expected to be essential and valuable tools in the treatment of psychiatric disorders. In the current article, we have summarized data obtained from animal models of depressive disorder and transgenic mouse models. We also focus on previously published research data of clinical studies on corticotropin-releasing hormone (CRH), galanin (GAL), neuropeptide Y (NPY), neuropeptide S (NPS), Oxytocin (OXT), vasopressin (VP), cholecystokinin (CCK), and melanin-concentrating hormone (MCH) stress research fields.
Collapse
|
7
|
Millón C, Flores-Burgess A, Gago B, Alén F, Orio L, García-Durán L, Narváez JA, Fuxe K, Santín L, Díaz-Cabiale Z. Role of the galanin N-terminal fragment (1-15) in anhedonia: Involvement of the dopaminergic mesolimbic system. J Psychopharmacol 2019; 33:737-747. [PMID: 31081442 DOI: 10.1177/0269881119844188] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND Anhedonia is a core feature of depressive disorders. The galanin N-terminal fragment (1-15) plays a role in mood regulation since it induces depression and anxiogenic-like effects in rats. In this study, we analysed galanin N-terminal fragment (1-15) actions in anhedonic-like behaviours in rats using operant and non-operant tests and the areas involved with these effects. METHODS Galanin N-terminal fragment (1-15) effects were analysed in saccharin self-administration, sucrose preference, novelty-suppressed feeding and female urine sniffing tests. The areas involved in galanin N-terminal fragment (1-15)-mediated effects were studied with positron emission tomography for in vivo imaging, and we analysed the ventral tegmental area and nucleus accumbens. Galanin N-terminal fragment (1-15) had effects on the mRNA expression of the dopamine transporters Dat and Vmat2; the C-Fos gene; the dopamine receptors D1, D2, D3, D5; and the galanin receptors 1 and 2. RESULTS Galanin N-terminal fragment (1-15) at a concentration of 3 nmol induced a strong anhedonia-like phenotype in all tests. The involvement of galanin receptor 2 was demonstrated with the galanin receptor 2 antagonist M871 (3 nmol). The 18F-fluorodeoxyglucose positron emission tomography images indicated the action of galanin N-terminal fragment (1-15) over several nuclei of the limbic system. Galanin N-terminal fragment (1-15)-mediated effects also involved changes in the expression of Dat, Vmat2, D3 and galanin receptors in the ventral tegmental area as well as the expression of C-Fos, D1, D2 and D3 and TH immunoreactivity in the nucleus accumbens. CONCLUSIONS Our results indicated that galanin N-terminal fragment (1-15) exerts strong anhedonic-like effects and that this effect was accompanied by changes in the dopaminergic mesolimbic system. These results may provide a basis for the development of novel therapeutic strategies using galanin N-terminal fragment (1-15) analogues for the treatment of depression and reward-related diseases.
Collapse
Affiliation(s)
- Carmelo Millón
- 1 Universidad de Málaga, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, Campus de Teatinos s/n, 29071, Málaga, Spain.,2 Departamento de Psicobiología y Metodología en Ciencias del Comportamiento, Facultad de Psicología, Universidad Complutense de Madrid, Madrid, Spain
| | - Antonio Flores-Burgess
- 1 Universidad de Málaga, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, Campus de Teatinos s/n, 29071, Málaga, Spain
| | - Belén Gago
- 1 Universidad de Málaga, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, Campus de Teatinos s/n, 29071, Málaga, Spain
| | - Francisco Alén
- 2 Departamento de Psicobiología y Metodología en Ciencias del Comportamiento, Facultad de Psicología, Universidad Complutense de Madrid, Madrid, Spain
| | - Laura Orio
- 2 Departamento de Psicobiología y Metodología en Ciencias del Comportamiento, Facultad de Psicología, Universidad Complutense de Madrid, Madrid, Spain
| | - Laura García-Durán
- 1 Universidad de Málaga, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, Campus de Teatinos s/n, 29071, Málaga, Spain
| | - José A Narváez
- 1 Universidad de Málaga, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, Campus de Teatinos s/n, 29071, Málaga, Spain
| | - Kjell Fuxe
- 3 Department of Neuroscience, Karolinska Institute, Stockholm, Sweden
| | - Luis Santín
- 4 Universidad de Málaga, Facultad de Psicología, Instituto de Investigación Biomédica de Málaga, Campus de Teatinos s/n, 29071, Málaga, Spain
| | - Zaida Díaz-Cabiale
- 1 Universidad de Málaga, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, Campus de Teatinos s/n, 29071, Málaga, Spain
| |
Collapse
|
8
|
Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines. Adv Pharmacol Sci 2019; 2019:7943481. [PMID: 30719038 PMCID: PMC6335777 DOI: 10.1155/2019/7943481] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Revised: 11/27/2018] [Accepted: 12/05/2018] [Indexed: 01/26/2023] Open
Abstract
Depression is currently recognized as a crucial problem in everyday clinical practice, in light of ever-increasing rates of prevalence, as well as disability, morbidity, and mortality related to this disorder. Currently available antidepressant drugs are notoriously problematic, with suboptimal remission rates and troubling side-effect profiles. Their mechanisms of action focus on the monoamine hypothesis for depression, which centers on the disruption of serotonergic, noradrenergic, and dopaminergic neurotransmission in the brain. Nevertheless, views on the pathophysiology of depression have evolved notably, and the comprehension of depression as a complex neuroendocrine disorder with important systemic implications has sparked interest in a myriad of novel neuropsychopharmacological approaches. Innovative pharmacological targets beyond monoamines include glutamatergic and GABAergic neurotransmission, brain-derived neurotrophic factor, various endocrine axes, as well as several neurosteroids, neuropeptides, opioids, endocannabinoids and endovanilloids. This review summarizes current knowledge on these pharmacological targets and their potential utility in the clinical management of depression.
Collapse
|
9
|
Hökfelt T, Barde S, Xu ZQD, Kuteeva E, Rüegg J, Le Maitre E, Risling M, Kehr J, Ihnatko R, Theodorsson E, Palkovits M, Deakin W, Bagdy G, Juhasz G, Prud’homme HJ, Mechawar N, Diaz-Heijtz R, Ögren SO. Neuropeptide and Small Transmitter Coexistence: Fundamental Studies and Relevance to Mental Illness. Front Neural Circuits 2018; 12:106. [PMID: 30627087 PMCID: PMC6309708 DOI: 10.3389/fncir.2018.00106] [Citation(s) in RCA: 70] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2018] [Accepted: 11/05/2018] [Indexed: 12/31/2022] Open
Abstract
Neuropeptides are auxiliary messenger molecules that always co-exist in nerve cells with one or more small molecule (classic) neurotransmitters. Neuropeptides act both as transmitters and trophic factors, and play a role particularly when the nervous system is challenged, as by injury, pain or stress. Here neuropeptides and coexistence in mammals are reviewed, but with special focus on the 29/30 amino acid galanin and its three receptors GalR1, -R2 and -R3. In particular, galanin's role as a co-transmitter in both rodent and human noradrenergic locus coeruleus (LC) neurons is addressed. Extensive experimental animal data strongly suggest a role for the galanin system in depression-like behavior. The translational potential of these results was tested by studying the galanin system in postmortem human brains, first in normal brains, and then in a comparison of five regions of brains obtained from depressed people who committed suicide, and from matched controls. The distribution of galanin and the four galanin system transcripts in the normal human brain was determined, and selective and parallel changes in levels of transcripts and DNA methylation for galanin and its three receptors were assessed in depressed patients who committed suicide: upregulation of transcripts, e.g., for galanin and GalR3 in LC, paralleled by a decrease in DNA methylation, suggesting involvement of epigenetic mechanisms. It is hypothesized that, when exposed to severe stress, the noradrenergic LC neurons fire in bursts and release galanin from their soma/dendrites. Galanin then acts on somato-dendritic, inhibitory galanin autoreceptors, opening potassium channels and inhibiting firing. The purpose of these autoreceptors is to act as a 'brake' to prevent overexcitation, a brake that is also part of resilience to stress that protects against depression. Depression then arises when the inhibition is too strong and long lasting - a maladaption, allostatic load, leading to depletion of NA levels in the forebrain. It is suggested that disinhibition by a galanin antagonist may have antidepressant activity by restoring forebrain NA levels. A role of galanin in depression is also supported by a recent candidate gene study, showing that variants in genes for galanin and its three receptors confer increased risk of depression and anxiety in people who experienced childhood adversity or recent negative life events. In summary, galanin, a neuropeptide coexisting in LC neurons, may participate in the mechanism underlying resilience against a serious and common disorder, MDD. Existing and further results may lead to an increased understanding of how this illness develops, which in turn could provide a basis for its treatment.
Collapse
Affiliation(s)
- Tomas Hökfelt
- Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Swapnali Barde
- Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Zhi-Qing David Xu
- Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
- Department of Neurobiology, Beijing Key Laboratory of Neural Regeneration and Repair, Beijing Laboratory of Brain Disorders (Ministry of Science and Technology), Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China
| | - Eugenia Kuteeva
- Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Joelle Rüegg
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
- The Center for Molecular Medicine, Stockholm, Sweden
- Swedish Toxicology Sciences Research Center, Swetox, Södertälje, Sweden
| | - Erwan Le Maitre
- Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Mårten Risling
- Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Jan Kehr
- Pronexus Analytical AB, Solna, Sweden
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
| | - Robert Ihnatko
- Department of Clinical Chemistry, Linköping University, Linköping, Sweden
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
| | - Elvar Theodorsson
- Department of Clinical Chemistry, Linköping University, Linköping, Sweden
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
| | - Miklos Palkovits
- Department of Anatomy, Histology and Embryology, Semmelweis University, Budapest, Hungary
| | - William Deakin
- Neuroscience and Psychiatry Unit, University of Manchester, Manchester, United Kingdom
| | - Gyorgy Bagdy
- Department of Pharmacodynamics, Semmelweis University, Budapest, Hungary
- MTA-SE Neuropsychopharmacology and Neurochemistry Research Group, Hungarian Academy of Sciences, Semmelweis University, Budapest, Hungary
- NAP 2-SE New Antidepressant Target Research Group, Hungarian Brain Research Program, Semmelweis University, Budapest, Hungary
| | - Gabriella Juhasz
- Neuroscience and Psychiatry Unit, University of Manchester, Manchester, United Kingdom
- Department of Pharmacodynamics, Semmelweis University, Budapest, Hungary
- SE-NAP2 Genetic Brain Imaging Migraine Research Group, Hungarian Brain Research Program, Semmelweis University, Budapest, Hungary
| | | | - Naguib Mechawar
- Douglas Hospital Research Centre, Verdun, QC, Canada
- Department of Psychiatry, McGill University, Montreal, QC, Canada
| | | | - Sven Ove Ögren
- Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
10
|
Fang P, Yu M, Wan D, Zhang L, Han L, Shen Z, Shi M, Zhu Y, Zhang Z, Bo P. Regulatory effects of galanin system on development of several age-related chronic diseases. Exp Gerontol 2017; 95:88-97. [DOI: 10.1016/j.exger.2017.04.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Revised: 04/21/2017] [Accepted: 04/24/2017] [Indexed: 02/07/2023]
|
11
|
Millón C, Flores-Burgess A, Narváez M, Borroto-Escuela DO, Gago B, Santín L, Castilla-Ortega E, Narváez JÁ, Fuxe K, Díaz-Cabiale Z. The neuropeptides Galanin and Galanin(1-15) in depression-like behaviours. Neuropeptides 2017; 64:39-45. [PMID: 28196617 DOI: 10.1016/j.npep.2017.01.004] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2016] [Revised: 01/24/2017] [Accepted: 01/24/2017] [Indexed: 12/11/2022]
Abstract
Galanin is a 29 amino acid neuropeptide widely distributed in neurons within the central nervous system. Galanin exerts its biological activities through three different G protein-receptors and participates in a number of functions, including mood regulation. Not only Galanin but also Galanin N-terminal fragments like Galanin(1-15) are active at the central level. In this work, we review the latest findings in studies on Galanin and Galanin(1-15) in depression-related behaviours. Our focus is on animal models for depression, and we pay some attention to research data obtained in human studies. Since Serotonin (5-HT), especially through 5-HT1A, and Galanin receptors interact at both pre-and postsynaptic level, the development of drugs targeting potential GAL1-GAL2-5-HT1A heteroreceptor complexes linked to the raphe-hippocampal 5-HT neurons may represent new treatment strategies in depression.
Collapse
Affiliation(s)
- Carmelo Millón
- Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Departamento de Fisiología, Campus de Teatinos s/n, 29071 Málaga, Spain.
| | - Antonio Flores-Burgess
- Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Departamento de Fisiología, Campus de Teatinos s/n, 29071 Málaga, Spain
| | - Manuel Narváez
- Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Departamento de Fisiología, Campus de Teatinos s/n, 29071 Málaga, Spain
| | | | - Belén Gago
- Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Departamento de Fisiología, Campus de Teatinos s/n, 29071 Málaga, Spain
| | - Luis Santín
- Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, Facultad de Psicología, Departamento de Psicobiología, Campus de Teatinos s/n, 29071 Málaga, Spain
| | - Estela Castilla-Ortega
- Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, Facultad de Psicología, Departamento de Psicobiología, Campus de Teatinos s/n, 29071 Málaga, Spain
| | - José Ángel Narváez
- Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Departamento de Fisiología, Campus de Teatinos s/n, 29071 Málaga, Spain
| | - Kjell Fuxe
- Department of Neuroscience, Karolinska Institute, Stockholm, Sweden
| | - Zaida Díaz-Cabiale
- Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Departamento de Fisiología, Campus de Teatinos s/n, 29071 Málaga, Spain
| |
Collapse
|
12
|
The galanin-3 receptor antagonist, SNAP 37889, suppresses alcohol drinking and morphine self-administration in mice. Neuropharmacology 2017; 118:1-12. [DOI: 10.1016/j.neuropharm.2017.03.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2016] [Revised: 02/17/2017] [Accepted: 03/02/2017] [Indexed: 02/07/2023]
|
13
|
Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide. Proc Natl Acad Sci U S A 2016; 113:E8472-E8481. [PMID: 27940914 DOI: 10.1073/pnas.1617824113] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Major depressive disorder (MDD) is a substantial burden to patients, families, and society, but many patients cannot be treated adequately. Rodent experiments suggest that the neuropeptide galanin (GAL) and its three G protein-coupled receptors, GAL1-3, are involved in mood regulation. To explore the translational potential of these results, we assessed the transcript levels (by quantitative PCR), DNA methylation status (by bisulfite pyrosequencing), and GAL peptide by RIA of the GAL system in postmortem brains from depressed persons who had committed suicide and controls. Transcripts for all four members were detected and showed marked regional variations, GAL and galanin receptor 1 (GALR1) being most abundant. Striking increases in GAL and GALR3 mRNA levels, especially in the noradrenergic locus coeruleus and the dorsal raphe nucleus, in parallel with decreased DNA methylation, were found in both male and female suicide subjects as compared with controls. In contrast, GAL and GALR3 transcript levels were decreased, GALR1 was increased, and DNA methylation was increased in the dorsolateral prefrontal cortex of male suicide subjects, however, there were no changes in the anterior cingulate cortex. Thus, GAL and its receptor GALR3 are differentially methylated and expressed in brains of MDD subjects in a region- and sex-specific manner. Such an epigenetic modification in GALR3, a hyperpolarizing receptor, might contribute to the dysregulation of noradrenergic and serotonergic neurons implicated in the pathogenesis of MDD. Thus, one may speculate that a GAL3 antagonist could have antidepressant properties by disinhibiting the firing of these neurons, resulting in increased release of noradrenaline and serotonin in forebrain areas involved in mood regulation.
Collapse
|
14
|
Wang P, Li H, Barde S, Zhang MD, Sun J, Wang T, Zhang P, Luo H, Wang Y, Yang Y, Wang C, Svenningsson P, Theodorsson E, Hökfelt TGM, Xu ZQD. Depression-like behavior in rat: Involvement of galanin receptor subtype 1 in the ventral periaqueductal gray. Proc Natl Acad Sci U S A 2016; 113:E4726-35. [PMID: 27457954 PMCID: PMC4987783 DOI: 10.1073/pnas.1609198113] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The neuropeptide galanin coexists in rat brain with serotonin in the dorsal raphe nucleus and with noradrenaline in the locus coeruleus (LC), and it has been suggested to be involved in depression. We studied rats exposed to chronic mild stress (CMS), a rodent model of depression. As expected, these rats showed several endophenotypes relevant to depression-like behavior compared with controls. All these endophenotypes were normalized after administration of a selective serotonin reuptake inhibitor. The transcripts for galanin and two of its receptors, galanin receptor 1 (GALR1) and GALR2, were analyzed with quantitative real-time PCR using laser capture microdissection in the following brain regions: the hippocampal formation, LC, and ventral periaqueductal gray (vPAG). Only Galr1 mRNA levels were significantly increased, and only in the latter region. After knocking down Galr1 in the vPAG with an siRNA technique, all parameters of the depressive behavioral phenotype were similar to controls. Thus, the depression-like behavior in rats exposed to CMS is likely related to an elevated expression of Galr1 in the vPAG, suggesting that a GALR1 antagonist could have antidepressant effects.
Collapse
Affiliation(s)
- Peng Wang
- Department of Neurobiology, Beijing Key Laboratory of Neural Regeneration and Repair, Beijing Laboratory of Brain Disorders (Ministry of Science and Technology), Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China
| | - Hui Li
- Department of Neurobiology, Beijing Key Laboratory of Neural Regeneration and Repair, Beijing Laboratory of Brain Disorders (Ministry of Science and Technology), Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China
| | - Swapnali Barde
- Department of Neuroscience, Karolinska Institutet, SE-17177 Stockholm, Sweden
| | - Ming-Dong Zhang
- Department of Neuroscience, Karolinska Institutet, SE-17177 Stockholm, Sweden; Division of Molecular Neurobiology, Department of Biochemistry and Biophysics, Karolinska Institutet, SE-17177 Stockholm, Sweden
| | - Jing Sun
- Department of Neurobiology, Beijing Key Laboratory of Neural Regeneration and Repair, Beijing Laboratory of Brain Disorders (Ministry of Science and Technology), Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China
| | - Tong Wang
- Department of Neurobiology, Beijing Key Laboratory of Neural Regeneration and Repair, Beijing Laboratory of Brain Disorders (Ministry of Science and Technology), Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China
| | - Pan Zhang
- Department of Neurobiology, Beijing Key Laboratory of Neural Regeneration and Repair, Beijing Laboratory of Brain Disorders (Ministry of Science and Technology), Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China
| | - Hanjiang Luo
- Department of Neurobiology, Beijing Key Laboratory of Neural Regeneration and Repair, Beijing Laboratory of Brain Disorders (Ministry of Science and Technology), Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China
| | - Yongjun Wang
- Anding Hospital, Capital Medical University, Beijing 100088, China
| | - Yutao Yang
- Department of Neurobiology, Beijing Key Laboratory of Neural Regeneration and Repair, Beijing Laboratory of Brain Disorders (Ministry of Science and Technology), Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China
| | - Chuanyue Wang
- Anding Hospital, Capital Medical University, Beijing 100088, China
| | - Per Svenningsson
- Center for Molecular Medicine, Department of Neurology and Clinical Neuroscience, Karolinska Institutet and Karolinska University Hospital, SE-17176 Stockholm, Sweden
| | - Elvar Theodorsson
- Department of Clinical Chemistry and Department of Clinical and Experimental Medicine, Linkoping University, SE-58183 Linkoping, Sweden
| | - Tomas G M Hökfelt
- Department of Neuroscience, Karolinska Institutet, SE-17177 Stockholm, Sweden;
| | - Zhi-Qing David Xu
- Department of Neurobiology, Beijing Key Laboratory of Neural Regeneration and Repair, Beijing Laboratory of Brain Disorders (Ministry of Science and Technology), Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China;
| |
Collapse
|
15
|
Petschner P, Juhasz G, Tamasi V, Adori C, Tothfalusi L, Hökfelt T, Bagdy G. Chronic venlafaxine treatment fails to alter the levels of galanin system transcripts in normal rats. Neuropeptides 2016; 57:65-70. [PMID: 26891823 DOI: 10.1016/j.npep.2016.01.010] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/05/2016] [Revised: 01/22/2016] [Accepted: 01/31/2016] [Indexed: 11/16/2022]
Abstract
It is widely accepted that efficacy and speed of current antidepressants' therapeutic effect are far from optimal. Thus, there is a need for the development of antidepressants with new mechanisms of action. The neuropeptide galanin and its receptors (GalR1, GalR2 and GalR3) are among the promising targets. However, it is not clear whether or not the galanin system is involved in the antidepressant effect exerted by the currently much used inhibitors of the reuptake of serotonin and/or noradrenaline. To answer this question we administered the selective serotonin and noradrenaline reuptake inhibitor (SNRI) venlafaxine (40mg/kg/day via osmotic minipumps) to normal rats and examined the levels of the transcripts for galanin and GalR1-3 after a 3-week venlafaxine treatment in the dorsal raphe, hippocampus and frontal cortex. These areas are known to be involved in the effects of antidepressants and in depression itself. Venlafaxine failed to alter the expression of any of the galanin system genes in these areas. Our results show that one of the most efficient, currently used SNRIs does not alter transcript levels of galanin or its three receptors in normal rats. These findings suggest that the pro- and antidepressive-like effects of galanin reported in animal experiments may employ a novel mechanism(s).
Collapse
Affiliation(s)
- Peter Petschner
- Department of Pharmacodynamics, Semmelweis University, H-1089, Nagyvarad ter 4., Budapest, Hungary; MTA-SE Neuropsychopharmacology & Neurochemistry Research Group, H-1089, Nagyvarad ter 4., Budapest, Hungary
| | - Gabriella Juhasz
- Department of Pharmacodynamics, Semmelweis University, H-1089, Nagyvarad ter 4., Budapest, Hungary; MTA-SE Neuropsychopharmacology & Neurochemistry Research Group, H-1089, Nagyvarad ter 4., Budapest, Hungary; MTA-SE-NAP B Genetic Brain Imaging Migraine Research Group, Hungarian Academy of Sciences, Semmelweis University, Hungary
| | - Viola Tamasi
- Department of Genetics-, Cell and Immunobiology, Semmelweis University, H-1089, Nagyvarad ter 4., Budapest, Hungary
| | - Csaba Adori
- Department of Pharmacodynamics, Semmelweis University, H-1089, Nagyvarad ter 4., Budapest, Hungary; Retzius Laboratory, Department of Neuroscience, Karolinska Institutet, Retzius väg 8, 17177, Stockholm, Sweden
| | - Laszlo Tothfalusi
- Department of Pharmacodynamics, Semmelweis University, H-1089, Nagyvarad ter 4., Budapest, Hungary
| | - Tomas Hökfelt
- Retzius Laboratory, Department of Neuroscience, Karolinska Institutet, Retzius väg 8, 17177, Stockholm, Sweden
| | - Gyorgy Bagdy
- Department of Pharmacodynamics, Semmelweis University, H-1089, Nagyvarad ter 4., Budapest, Hungary; MTA-SE Neuropsychopharmacology & Neurochemistry Research Group, H-1089, Nagyvarad ter 4., Budapest, Hungary.
| |
Collapse
|
16
|
Narváez M, Borroto-Escuela DO, Millón C, Gago B, Flores-Burgess A, Santín L, Fuxe K, Narváez JA, Díaz-Cabiale Z. Galanin receptor 2-neuropeptide Y Y1 receptor interactions in the dentate gyrus are related with antidepressant-like effects. Brain Struct Funct 2015; 221:4129-4139. [DOI: 10.1007/s00429-015-1153-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Accepted: 11/19/2015] [Indexed: 11/30/2022]
|
17
|
Freimann K, Kurrikoff K, Langel Ü. Galanin receptors as a potential target for neurological disease. Expert Opin Ther Targets 2015. [PMID: 26220265 DOI: 10.1517/14728222.2015.1072513] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
INTRODUCTION Galanin is a 29/30 amino acid long neuropeptide that is widely expressed in the brains of many mammals. Galanin exerts its biological activities through three different G protein-coupled receptors, GalR1, GalR2 and GalR3. The widespread distribution of galanin and its receptors in the CNS and the various physiological and pharmacological effects of galanin make the galanin receptors attractive drug targets. AREAS COVERED This review provides an overview of the role of galanin and its receptors in the CNS, the involvement of the galaninergic system in various neurological diseases and the development of new galanin receptor-specific ligands. EXPERT OPINION Recent advances and novel approaches in migrating the directions of subtype-selective ligand development and chemical modifications of the peptide backbone highlight the importance of the galanin neurochemical system as a potential target for drug development.
Collapse
Affiliation(s)
- Krista Freimann
- a 1 University of Tartu, Institute of Technology , Tartu, Estonia +372 737 4871 ;
| | - Kaido Kurrikoff
- b 2 University of Tartu, Institute of Technology , Tartu, Estonia
| | - Ülo Langel
- c 3 University of Tartu, Institute of Technology , Tartu, Estonia.,d 4 Stockholm University, Arrhenius Laboratories for Natural Science, Department of Neurochemistry , Stockholm, Sweden
| |
Collapse
|
18
|
Millón C, Flores-Burgess A, Narváez M, Borroto-Escuela DO, Santín L, Parrado C, Narváez JA, Fuxe K, Díaz-Cabiale Z. A role for galanin N-terminal fragment (1-15) in anxiety- and depression-related behaviors in rats. Int J Neuropsychopharmacol 2015; 18:pyu064. [PMID: 25522404 PMCID: PMC4360234 DOI: 10.1093/ijnp/pyu064] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
BACKGROUND Galanin (GAL) plays a role in mood regulation. In this study we analyzed the action of the active N-terminal fragment [GAL(1-15)] in anxiety- and depression-related behavioral tests in rats. METHODS The effect of GAL(1-15) was analyzed in the forced swimming test, tail suspension test, open field test, and light/dark test. The proximity of GAL1 and GAL2 receptors was examined with the proximity ligation assay (PLA). We tested the GAL receptors involved in GAL(1-15) effects with the GAL2 receptor antagonist M871 and with an in vivo model of siRNA GAL2 receptor knockdown or siRNA GAL1 receptor knockdown rats. The effects of GAL(1-15) were also studied in the cell line RN33B. RESULTS GAL(1-15) induced strong depression-like and anxiogenic-like effects in all the tests. These effects were stronger than the ones induced by GAL. The involvement of the GAL2 receptor was demonstrated with M871 and with the siRNA GAL2 receptor knockdown rats. The PLA indicated the possible existence of GAL1 and GAL2 heteroreceptor complexes in the dorsal hippocampus and especially in the dorsal raphe nucleus. In the siRNA GAL1 receptor knockdown rats the behavioral actions of GAL(1-15) disappeared, and in the siRNA GAL2 receptor knockdown rats the reductions of the behavioral actions of GAL(1-15) was linked to a disappearance of PLA. In the cell line RN33B, GAL(1-15) decreased 5-HT immunoreactivity more strongly than GAL. CONCLUSIONS Our results indicate that GAL(1-15) exerts strong depression-related and anxiogenic-like effects and may give the basis for the development of drugs targeting GAL1 and GAL2 heteroreceptor complexes in the raphe-limbic system for the treatment of depression and anxiety.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Zaida Díaz-Cabiale
- Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Campus de Teatinos s/n, 29071 Málaga, España (PhD Millón, Flores-Burgess, M Narváez, Parrado, JA Narváez, and Díaz-Cabiale); Department of Neuroscience, Karolinska Institute, Stockholm, Sweden (PhD Borroto-Escuela and Fuxe); Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, Facultad de Psicología, Campus de Teatinos s/n, 29071 Málaga, España (PhD Santín).
| |
Collapse
|
19
|
Faster, better, stronger: towards new antidepressant therapeutic strategies. Eur J Pharmacol 2014; 753:32-50. [PMID: 25092200 DOI: 10.1016/j.ejphar.2014.07.046] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2014] [Revised: 05/28/2014] [Accepted: 07/24/2014] [Indexed: 12/26/2022]
Abstract
Major depression is a highly prevalent disorder and is predicted to be the second leading cause of disease burden by 2020. Although many antidepressant drugs are currently available, they are far from optimal. Approximately 50% of patients do not respond to initial first line antidepressant treatment, while approximately one third fail to achieve remission following several pharmacological interventions. Furthermore, several weeks or months of treatment are often required before clinical improvement, if any, is reported. Moreover, most of the commonly used antidepressants have been primarily designed to increase synaptic availability of serotonin and/or noradrenaline and although they are of therapeutic benefit to many patients, it is clear that other therapeutic targets are required if we are going to improve the response and remission rates. It is clear that more effective, rapid-acting antidepressants with novel mechanisms of action are required. The purpose of this review is to outline the current strategies that are being taken in both preclinical and clinical settings for identifying superior antidepressant drugs. The realisation that ketamine has rapid antidepressant-like effects in treatment resistant patients has reenergised the field. Further, developing an understanding of the mechanisms underlying the rapid antidepressant effects in treatment-resistant patients by drugs such as ketamine may uncover novel therapeutic targets that can be exploited to meet the Olympian challenge of developing faster, better and stronger antidepressant drugs.
Collapse
|
20
|
The potential antidepressant and antidiabetic effects of galanin system. Pharmacol Biochem Behav 2014; 120:82-7. [DOI: 10.1016/j.pbb.2014.02.018] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2013] [Revised: 02/17/2014] [Accepted: 02/22/2014] [Indexed: 11/17/2022]
|
21
|
Abstract
The neuropeptide galanin (GAL) is widely distributed in the central and peripheral nervous systems. It is a modulator of various physiological and pathological processes, and it mediates its effects via three G protein-coupled receptors (GAL1-3 receptors). A role for GAL as a modulator of mood and anxiety was suggested, because GAL and its receptors are highly expressed in limbic brain structures of rodents. In recent years, numerous studies of animal models have suggested an involvement of GAL and GAL1 and GAL2 receptors in anxiety- and depression-related behavior. However, to date, there is sparse literature implicating GAL3 receptors in behavioral functions. Therefore, we studied the behavior of GAL3 receptor-deficient (GAL3-KO) mice to elucidate whether GAL3 receptors are involved in mediating behavior-associated actions of GAL. The GAL3-KO mouse line exhibited normal breeding and physical development. In addition to behavioral tests, phenotypic characterization included analysis of hematology, amino acid profiles, metabolism, and sudomotor function. In contrast to WT littermates, male GAL3-KO mice exhibited an anxiety-like phenotype in the elevated plus maze, open field, and light/dark box tests, and they were less socially affiliated than WT animals to a stranger mouse in a social interaction test. In conclusion, our data suggest involvement of GAL3 receptors in GAL-mediated effects on mood, anxiety, and behavior, making it a possible target for alternative treatment strategies for mood disorders.
Collapse
|
22
|
Saar I, Lahe J, Langel K, Runesson J, Webling K, Järv J, Rytkönen J, Närvänen A, Bartfai T, Kurrikoff K, Langel Ü. Novel systemically active galanin receptor 2 ligands in depression-like behavior. J Neurochem 2013; 127:114-23. [PMID: 23600864 DOI: 10.1111/jnc.12274] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2012] [Revised: 03/31/2013] [Accepted: 03/31/2013] [Indexed: 11/30/2022]
Abstract
Neuropeptide galanin and its three G-protein coupled receptors, galanin receptor type 1-galanin receptor type 3 (GalR1-GalR3), are involved in the regulation of numerous physiological and disease processes, and thus represent tremendous potential in neuroscience research and novel drug lead development. One of the areas where galanin is involved is depression. Previous studies have suggested that activation of GalR2 leads to attenuation of depression-like behavior. Unfortunately, lack of in vivo usable subtype specific ligands hinders testing the role of galanin in depression mechanisms. In this article, we utilize an approach of increasing in vivo usability of peptide-based ligands, acting upon CNS. Thus, we have synthesized a series of novel systemically active galanin analogs, with modest preferential binding toward GalR2. We have shown that specific chemical modifications to the galanin backbone increase brain levels upon i.v. injection of the peptides. Several of the new peptides, similar to a common clinically used antidepressant medication imipramine, exerted antidepressant-like effect in forced swim test, a mouse model of depression, at a surprisingly low dose range (< 0.5 mg/kg). We chose one of the peptides, J18, for more thorough study, and showed its efficacy also in another mouse depression model (tail suspension test), and demonstrated that its antidepressant-like effect upon i.v. administration can be blocked by i.c.v. galanin receptor antagonist M35. The effect of the J18 was also abolished in GalR2KO animals. All this suggests that systemically administered peptide analog J18 exerts its biological effect through activation of GalR2 in the brain. The novel galanin analogs represent potential drug leads and a novel pharmaceutical intervention for depression.
Collapse
Affiliation(s)
- Indrek Saar
- Institute of Technology, University of Tartu, Tartu, Estonia; Department of Neurochemistry, Arrhenius Laboratories for Natural Sciences, Stockholm University, Stockholm, Sweden
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Distinct features of neurotransmitter systems in the human brain with focus on the galanin system in locus coeruleus and dorsal raphe. Proc Natl Acad Sci U S A 2013; 110:E536-45. [PMID: 23341594 DOI: 10.1073/pnas.1221378110] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Using riboprobe in situ hybridization, we studied the localization of the transcripts for the neuropeptide galanin and its receptors (GalR1-R3), tryptophan hydroxylase 2, tyrosine hydroxylase, and nitric oxide synthase as well as the three vesicular glutamate transporters (VGLUT 1-3) in the locus coeruleus (LC) and the dorsal raphe nucleus (DRN) regions of postmortem human brains. Quantitative real-time PCR (qPCR) was used also. Galanin and GalR3 mRNA were found in many noradrenergic LC neurons, and GalR3 overlapped with serotonin neurons in the DRN. The qPCR analysis at the LC level ranked the transcripts in the following order in the LC: galanin >> GalR3 >> GalR1 > GalR2; in the DRN the ranking was galanin >> GalR3 >> GalR1 = GalR2. In forebrain regions the ranking was GalR1 > galanin > GalR2. VGLUT1 and -2 were strongly expressed in the pontine nuclei but could not be detected in LC or serotonin neurons. VGLUT2 transcripts were found in very small, nonpigmented cells in the LC and in the lateral and dorsal aspects of the periaqueductal central gray. Nitric oxide synthase was not detected in serotonin neurons. These findings show distinct differences between the human brain and rodents, especially rat, in the distribution of the galanin system and some other transmitter systems. For example, GalR3 seems to be the important galanin receptor in both the human LC and DRN versus GalR1 and -2 in the rodent brain. Such knowledge may be important when considering therapeutic principles and drug development.
Collapse
|
24
|
Saar I, Runesson J, Järv J, Kurrikoff K, Langel Ü. Novel Galanin Receptor Subtype Specific Ligand in Depression Like Behavior. Neurochem Res 2012. [DOI: 10.1007/s11064-012-0933-8] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
25
|
Hill MN, Hellemans KGC, Verma P, Gorzalka BB, Weinberg J. Neurobiology of chronic mild stress: parallels to major depression. Neurosci Biobehav Rev 2012; 36:2085-117. [PMID: 22776763 PMCID: PMC4821201 DOI: 10.1016/j.neubiorev.2012.07.001] [Citation(s) in RCA: 304] [Impact Index Per Article: 25.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2011] [Revised: 06/21/2012] [Accepted: 07/01/2012] [Indexed: 01/28/2023]
Abstract
The chronic mild (or unpredictable/variable) stress (CMS) model was developed as an animal model of depression more than 20 years ago. The foundation of this model was that following long-term exposure to a series of mild, but unpredictable stressors, animals would develop a state of impaired reward salience that was akin to the anhedonia observed in major depressive disorder. In the time since its inception, this model has also been used for a variety of studies examining neurobiological variables that are associated with depression, despite the fact that this model has never been critically examined to validate that the neurobiological changes induced by CMS are parallel to those documented in depressive disorder. The aim of the current review is to summarize the current state of knowledge regarding the effects of chronic mild stress on neurobiological variables, such as neurochemistry, neurochemical receptor expression and functionality, neurotrophin expression and cellular plasticity. These findings are then compared to those of clinical research examining common variables in populations with depressive disorders to determine if the changes observed following chronic mild stress are in fact consistent with those observed in major depression. We conclude that the chronic mild stress paradigm: (1) evokes an array of neurobiological changes that mirror those seen in depressive disorders and (2) may be a suitable tool to investigate novel systems that could be disturbed in depression, and thus aid in the development of novel targets for the treatment of depression.
Collapse
Affiliation(s)
- Matthew N Hill
- Departments of Cell Biology and Anatomy, Hotchkiss Brain Institute, University of Calgary, Calgary, AB Canada.
| | | | | | | | | |
Collapse
|
26
|
Vilches JJ, Wynick D, Kofler B, Lang R, Navarro X. Sudomotor function and sweat gland innervation in galanin knockout mice. Neuropeptides 2012; 46:151-5. [PMID: 22698811 DOI: 10.1016/j.npep.2012.05.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2012] [Revised: 05/15/2012] [Accepted: 05/17/2012] [Indexed: 12/13/2022]
Abstract
The presence of galanin and galanin binding sites in sweat gland has been demonstrated previously. In order to investigate whether galanin can influence sweat gland function, we compared sweating induced in footpads of wild type and galanin knockout mice by cholinergic and thermal stimulation using the silicone impression technique. Pilocarpine injections resulted in a similar number of reactive sweat glands and non-significant difference in the amount of sweat secretion in wild type and galanin knockout mice. However, thermal stimulation led to a significant increase in the number of secreting sweat glands in galanin knockout mice. To further evaluate possible differences in the innervation of sweat glands that could explain differences in their secretory activity, immunohistochemical labeling of cutaneous and sudomotor innervations against protein gene product 9.5, vasoactive intestinal polypeptide and choline acetyltransferase in plantar pads was performed. Immunohistochemical analysis revealed no significant differences in the distribution and intensity of the innervations between wild type mice and galanin knockout mice. Although our results indicate normal cholinergic responses and innervation of the sweat glands in galanin knockout mice, they also demonstrate that galanin plays a role in regulating the sudomotor activity in response to thermal stimulation.
Collapse
Affiliation(s)
- Jorge J Vilches
- Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences and CIBERNED, Universitat Autònoma de Barcelona, Bellaterra, Spain
| | | | | | | | | |
Collapse
|
27
|
Fuxe K, Borroto-Escuela DO, Romero-Fernandez W, Tarakanov AO, Calvo F, Garriga P, Tena M, Narvaez M, Millón C, Parrado C, Ciruela F, Agnati LF, Narvaez JA, Díaz-Cabiale Z. On the existence and function of galanin receptor heteromers in the central nervous system. Front Endocrinol (Lausanne) 2012; 3:127. [PMID: 23112793 PMCID: PMC3481144 DOI: 10.3389/fendo.2012.00127] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/26/2012] [Accepted: 10/05/2012] [Indexed: 12/04/2022] Open
Abstract
Galanin receptor (GalR) subtypes 1-3 linked to central galanin neurons may form heteromers with each other and other types of G protein-coupled receptors in the central nervous system (CNS). These heteromers may be one molecular mechanism for galanin peptides and their N-terminal fragments (gal 1-15) to modulate the function of different types of glia-neuronal networks in the CNS, especially the emotional and the cardiovascular networks. GalR-5-HT1A heteromers likely exist with antagonistic GalR-5-HT1A receptor-receptor interactions in the ascending midbrain raphe 5-HT neuron systems and their target regions. They represent a novel target for antidepressant drugs. Evidence is given for the existence of GalR1-5-HT1A heteromers in cellular models with trans-inhibition of the protomer signaling. A GalR1-GalR2 heteromer is proposed to be a galanin N-terminal fragment preferring receptor (1-15) in the CNS. Furthermore, a GalR1-GalR2-5-HT1A heterotrimer is postulated to explain why only galanin (1-15) but not galanin (1-29) can antagonistically modulate the 5-HT1A receptors in the dorsal hippocampus rich in gal fragment binding sites. The results underline a putative role of different types of GalR-5-HT1A heteroreceptor complexes in depression. GalR antagonists may also have therapeutic actions in depression by blocking the antagonistic GalR-NPYY1 receptor interactions in putative GalR-NPYY1 receptor heteromers in the CNS resulting in increases in NPYY1 transmission and antidepressant effects. In contrast the galanin fragment receptor (a postulated GalR1-GalR2 heteromer) appears to be linked to the NPYY2 receptor enhancing the affinity of the NPYY2 binding sites in a putative GalR1-GalR2-NPYY2 heterotrimer. Finally, putative GalR-α2-adrenoreceptor heteromers with antagonistic receptor-receptor interactions may be a widespread mechanism in the CNS for integration of galanin and noradrenaline signals also of likely relevance for depression.
Collapse
Affiliation(s)
- Kjell Fuxe
- Department of Neuroscience, Karolinska InstitutetStockholm, Sweden
- *Correspondence: Kjell Fuxe, Department of Neuroscience, Karolinska Institutet, Retzius väg 8, 17177 Stockholm, Sweden. e-mail:
| | | | | | - Alexander O. Tarakanov
- St. Petersburg Institute for Informatics and Automation, Russian Academy of SciencesSaint Petersburg, Russia
| | - Feliciano Calvo
- Department of Neuroscience, Karolinska InstitutetStockholm, Sweden
| | - Pere Garriga
- Centre de Biotecnologia Molecular, Departament d’Enginyeria Química, Universitat Politécnica de CatalunyaBarcelona, Spain
| | - Mercé Tena
- Centre de Biotecnologia Molecular, Departament d’Enginyeria Química, Universitat Politécnica de CatalunyaBarcelona, Spain
| | - Manuel Narvaez
- Department of Physiology, School of Medicine, University of MálagaMálaga, Spain
| | - Carmelo Millón
- Department of Physiology, School of Medicine, University of MálagaMálaga, Spain
| | - Concepción Parrado
- Department of Histology, School of Medicine, University of MálagaMálaga, Spain
| | - Francisco Ciruela
- Unitat de Farmacologia, Departament Patologia i Terapéutica Experimental, Universitat de BarcelonaBarcelona, Spain
| | - Luigi F. Agnati
- Department of Biomedical Sciences, University of Modena and Reggio EmiliaModena, Italy
- Istituto di Ricovero e Cura a Carattere ScientificoLido Venice, Italy
| | - José A. Narvaez
- Department of Physiology, School of Medicine, University of MálagaMálaga, Spain
| | - Zaida Díaz-Cabiale
- Department of Physiology, School of Medicine, University of MálagaMálaga, Spain
| |
Collapse
|
28
|
Webling KEB, Runesson J, Bartfai T, Langel Ü. Galanin receptors and ligands. Front Endocrinol (Lausanne) 2012; 3:146. [PMID: 23233848 PMCID: PMC3516677 DOI: 10.3389/fendo.2012.00146] [Citation(s) in RCA: 94] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2012] [Accepted: 11/08/2012] [Indexed: 12/13/2022] Open
Abstract
The neuropeptide galanin was first discovered 30 years ago. Today, the galanin family consists of galanin, galanin-like peptide (GALP), galanin-message associated peptide (GMAP), and alarin and this family has been shown to be involved in a wide variety of biological and pathological functions. The effect is mediated through three GPCR subtypes, GalR1-3. The limited number of specific ligands to the galanin receptor subtypes has hindered the understanding of the individual effects of each receptor subtype. This review aims to summarize the current data of the importance of the galanin receptor subtypes and receptor subtype specific agonists and antagonists and their involvement in different biological and pathological functions.
Collapse
Affiliation(s)
- Kristin E. B. Webling
- Department of Neurochemistry, Arrhenius Laboratories for Natural Science, Stockholm UniversityStockholm, Sweden
- *Correspondence: Kristin E. B. Webling, Department of Neurochemistry, Arrhenius Laboratories for Natural Science, Stockholm University, Svante Arrheniusv. 21A, 10691 Stockholm, Sweden. e-mail:
| | - Johan Runesson
- Department of Neurochemistry, Arrhenius Laboratories for Natural Science, Stockholm UniversityStockholm, Sweden
| | - Tamas Bartfai
- Molecular and Integrative Neurosciences Department, The Scripps Research InstituteLa Jolla, CA, USA
| | - Ülo Langel
- Department of Neurochemistry, Arrhenius Laboratories for Natural Science, Stockholm UniversityStockholm, Sweden
- Institute of Technology, University of TartuTartu, Estonia
| |
Collapse
|
29
|
Davidson S, Lear M, Shanley L, Hing B, Baizan-Edge A, Herwig A, Quinn JP, Breen G, McGuffin P, Starkey A, Barrett P, MacKenzie A. Differential activity by polymorphic variants of a remote enhancer that supports galanin expression in the hypothalamus and amygdala: implications for obesity, depression and alcoholism. Neuropsychopharmacology 2011; 36:2211-21. [PMID: 21716262 PMCID: PMC3176579 DOI: 10.1038/npp.2011.93] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The expression of the galanin gene (GAL) in the paraventricular nucleus (PVN) and in the amygdala of higher vertebrates suggests the requirement for highly conserved, but unidentified, regulatory sequences that are critical to allow the galanin gene to control alcohol and fat intake and modulate mood. We used comparative genomics to identify a highly conserved sequence that lay 42 kb 5' of the human GAL transcriptional start site that we called GAL5.1. GAL5.1 activated promoter activity in neurones of the PVN, arcuate nucleus and amygdala that also expressed the galanin peptide. Analysis in neuroblastoma cells demonstrated that GAL5.1 acted as an enhancer of promoter activity after PKC activation. GAL5.1 contained two polymorphisms; rs2513280(C/G) and rs2513281(A/G), that occurred in two allelic combinations (GG or CA) where the dominant GG alelle occurred in 70-83 % of the human population. Intriguingly, both SNPs were found to be in LD (R(2) of 0.687) with another SNP (rs2156464) previously associated with major depressive disorder (MDD). Recreation of these alleles in reporter constructs and subsequent magnetofection into primary rat hypothalamic neurones showed that the CA allele was 40 % less active than the GG allele. This is consistent with the hypothesis that the weaker allele may affect food and alcohol preference. The linkage of the SNPs analysed in this study with a SNP previously associated with MDD together with the functioning of GAL5.1 as a PVN and amygdala specific enhancer represent a significant advance in our ability to understand alcoholism, obesity and major depressive disorder.
Collapse
Affiliation(s)
- Scott Davidson
- School of Medical Sciences, Institute of Medical Sciences, Foresterhill, University of Aberdeen, Aberdeen, Scotland, UK
| | - Marissa Lear
- School of Medical Sciences, Institute of Medical Sciences, Foresterhill, University of Aberdeen, Aberdeen, Scotland, UK
| | - Lynne Shanley
- School of Medical Sciences, Institute of Medical Sciences, Foresterhill, University of Aberdeen, Aberdeen, Scotland, UK
| | - Benjamin Hing
- School of Medical Sciences, Institute of Medical Sciences, Foresterhill, University of Aberdeen, Aberdeen, Scotland, UK
| | - Amanda Baizan-Edge
- School of Medical Sciences, Institute of Medical Sciences, Foresterhill, University of Aberdeen, Aberdeen, Scotland, UK
| | - Annika Herwig
- The Rowett Institute of Nutrition and Health, Aberdeen, Scotland, UK
| | - John P Quinn
- The Physiological Laboratory, School of Biomedical Sciences, Crown Street, University of Liverpool, Liverpool, UK
| | - Gerome Breen
- MRC SGDP Centre, Institute of Psychiatry, King's College London, DeCrespigny Park, London, UK
| | - Peter McGuffin
- MRC SGDP Centre, Institute of Psychiatry, King's College London, DeCrespigny Park, London, UK
| | - Andrew Starkey
- School of Engineering, Fraser Noble Building, Kings College, University of Aberdeen, Aberdeen, Scotland, UK
| | - Perry Barrett
- The Rowett Institute of Nutrition and Health, Aberdeen, Scotland, UK
| | - Alasdair MacKenzie
- School of Medical Sciences, Institute of Medical Sciences, Foresterhill, University of Aberdeen, Aberdeen, Scotland, UK,School of Medical Sciences, Institute of Medical Sciences, Foresterhill, University of Aberdeen, Aberdeen, Scotland, UK, Tel: +44 (0)1224 437380, Fax: +44 (0)1224 555719, E-mail:
| |
Collapse
|
30
|
Le Maître TW, Xia S, Le Maitre E, Dun XP, Lu J, Theodorsson E, Ogren SO, Hökfelt T, Xu ZQD. Galanin receptor 2 overexpressing mice display an antidepressive-like phenotype: possible involvement of the subiculum. Neuroscience 2011; 190:270-88. [PMID: 21672612 DOI: 10.1016/j.neuroscience.2011.05.015] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2011] [Revised: 04/21/2011] [Accepted: 05/04/2011] [Indexed: 01/13/2023]
Abstract
The behavioral phenotype of a transgenic mouse overexpressing a galanin receptor 2 (GalR2)-enhanced, green fluorescent protein (EGFP)-construct under the platelet-derived growth factor-B promoter, and of controls, was assessed in various behavioral tests, such as the Porsolt forced swim test, as well as the open field, elevated plus maze and passive avoidance tests. In addition, the distribution of GalR2-EGFP expressing cell bodies and processes was studied in the brain of these mice using histochemical methods. Three age groups of the transgenic mice demonstrated decreased levels of immobility in the forced swim test, indicative of antidepressive-like behavior and/or increased stress resistance. Anxiety-like behaviors, measured in two different tests, did not differ between the GalR2-overexpressing and the wild-type mice, nor did motor activity levels, emotional learning or memory behaviors. High levels of GalR2 mRNA and protein expression were observed in the presubiculum, subiculum, cingulate cortex, retrosplenial granular and agranular cortices, subregions of prefrontal cortex, and the olfactory bulb, regions which are directly or indirectly implicated in depression-like behavior. These results may contribute to the understanding of the pathophysiology of major depressive disorder and the role of GalR2 in the regulation of mood, and suggest a potential therapeutic effect by targeting the GalR2 for treatment of depressive disorders.
Collapse
Affiliation(s)
- T Wardi Le Maître
- Department of Neuroscience, Karolinska Institutet, Retzius Väg 8, S-17177 Stockholm, Sweden.
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Christiansen SH, Woldbye DPD. Regulation of the galanin system by repeated electroconvulsive seizures in mice. J Neurosci Res 2010; 88:3635-43. [PMID: 20936701 DOI: 10.1002/jnr.22517] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2010] [Revised: 07/30/2010] [Accepted: 08/26/2010] [Indexed: 11/07/2022]
Abstract
Even though induction of seizures by electroconvulsive stimulation (ECS) is a treatment widely used for major depression in humans, the working mechanism of ECS remains uncertain. The antiepileptic effect of ECS has been suggested to be involved in mediating the therapeutic effect of ECS. The neuropeptide galanin exerts antiepileptic and antidepressant-like effects and has also been implicated in the pathophysiology of depression. To explore a potential role of galanin in working mechanisms of ECS, the present study examined effects of repeated ECS on the galanin system using QRT-PCR, in situ hybridization, and [(125) I]galanin receptor binding. ECS was administered to adult mice daily for 14 days, and this paradigm was confirmed to exert antidepressant-like effect in the tail suspension test. Prominent increases in galanin gene expression were found in several brain regions involved in regulation of epileptic activity and depression, including the piriform cortex, hippocampal dentate gyrus, and amygdala. Likewise, GalR2 gene expression was up-regulated in both the central and the medial amygdala, whereas GalR1 gene expression showed a modest down-regulation in the medial amygdala. [(125) I]galanin receptor binding in the piriform cortex, hippocampus, and amygdala was found to be significantly down-regulated. These data show that the galanin system is regulated by repeated ECS in a number of brain regions implicated in seizure regulation and depression. These changes may play a role in the therapeutic effect of ECS.
Collapse
Affiliation(s)
- S H Christiansen
- Laboratory of Neuropsychiatry, Psychiatric Centre Copenhagen, and Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark
| | | |
Collapse
|
32
|
Ash BL, Zanatta SD, Williams SJ, Lawrence AJ, Djouma E. The galanin-3 receptor antagonist, SNAP 37889, reduces operant responding for ethanol in alcohol-preferring rats. ACTA ACUST UNITED AC 2010; 166:59-67. [PMID: 20736033 DOI: 10.1016/j.regpep.2010.08.009] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2010] [Revised: 08/17/2010] [Accepted: 08/18/2010] [Indexed: 11/25/2022]
Abstract
BACKGROUND/OBJECTIVE The galanin-3 receptor (GALR3) subtype has been identified as having a role in both feeding behaviour and the regulation of emotional states including anxiety. Despite the evidence for an association between galanin and alcohol, the current study is the first to explore the direct role of GALR3 in this context. The present study investigated the potential of the novel selective GALR3 antagonist, SNAP 37889, to reduce anxiety-like behaviour and voluntary ethanol consumption in the iP (alcohol-preferring) rat. This was achieved through a number of behavioural paradigms testing for anxiety, along with the operant self-administration model. RESULTS Overall, male iP rats treated with SNAP 37889 at a dose of 30 mg/kg (i.p.) did not show altered locomotor activity or changes in anxiety-like behaviour in the elevated plus maze or light-dark paradigms. Treatment with SNAP 37889 (30 mg/kg, i.p.) reduced operant responding for solutions containing ethanol, sucrose and saccharin. Collectively, results from the current study showed that SNAP 37889 (30 mg/kg, i.p.) is effective in reducing operant responding for ethanol, independent of a sedative effect. CONCLUSIONS These findings provide evidence that GALR3 antagonism reduces alcohol consumption and further suggest that GALR3 may be implicated in the rewarding effects of natural and drug reinforcers.
Collapse
Affiliation(s)
- Belinda L Ash
- School of Human Biosciences, La Trobe University, Bundoora, Victoria, Australia
| | | | | | | | | |
Collapse
|
33
|
Alldredge B. Pathogenic involvement of neuropeptides in anxiety and depression. Neuropeptides 2010; 44:215-24. [PMID: 20096456 DOI: 10.1016/j.npep.2009.12.014] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/14/2009] [Revised: 11/15/2009] [Accepted: 12/15/2009] [Indexed: 12/11/2022]
Abstract
Anxiety and depression are highly prevalent disorders of mood posing significant challenges to individuals and society. Current evidence indicates no single neurobiological determinant underpins these conditions and an integrated approach in both research and treatment is expedient. Basic, behavioral, and clinical science indicates various stress-responsive neuropeptides in the neuroendocrine, autonomic, and behavioral pathophysiology of stress-related disorders including anxiety and depression. This review draws on recent research to capture the consensus and implications of neuropeptide research concerning the pathogenesis of anxiety and depression.
Collapse
Affiliation(s)
- Brett Alldredge
- Kansas City University of Medicine and Bioscience, College of Medicine, 1705 Independence Ave., Kansas City, United States.
| |
Collapse
|
34
|
Rotzinger S, Lovejoy DA, Tan LA. Behavioral effects of neuropeptides in rodent models of depression and anxiety. Peptides 2010; 31:736-56. [PMID: 20026211 DOI: 10.1016/j.peptides.2009.12.015] [Citation(s) in RCA: 142] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2009] [Revised: 12/09/2009] [Accepted: 12/10/2009] [Indexed: 10/20/2022]
Abstract
In recent years, studies have advocated neuropeptide systems as modulators for the behavioral states found in mood disorders such as depression and anxiety disorders. Neuropeptides have been tested in traditional animal models and screening procedures that have been validated by known antidepressants and anxiolytics. However, it has become clear that although these tests are very useful, neuropeptides have distinct behavioral effects and dose-dependent characteristics, and therefore, use of these tests with neuropeptides must be done with an understanding of their unique characteristics. This review will focus on the behavioral actions of neuropeptides and their synthetic analogs, particularly in studies utilizing various preclinical tests of depression and anxiety. Specifically, the following neuropeptide systems will be reviewed: corticotropin-releasing factor (CRF), urocortin (Ucn), teneurin C-terminal associated peptide (TCAP), neuropeptide Y (NPY), arginine vasopressin (AVP), oxytocin, the Tyr-MIF-1 family, cholecystokinin (CCK), galanin, and substance P. These neuropeptide systems each have a unique role in the regulation of stress-like behavior, and therefore provide intriguing therapeutic targets for mood disorder treatment.
Collapse
Affiliation(s)
- Susan Rotzinger
- Department of Psychiatry, University of Toronto, Toronto, Canada
| | | | | |
Collapse
|
35
|
Mitsukawa K, Lu X, Bartfai T. Galanin, galanin receptors, and drug targets. EXPERIENTIA SUPPLEMENTUM (2012) 2010; 102:7-23. [PMID: 21299058 DOI: 10.1007/978-3-0346-0228-0_2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Galanin, a neuropeptide widely expressed in the central and peripheral nervous systems and in the endocrine system, has been shown to regulate numerous physiological and pathological processes through interactions with three G-protein-coupled receptors, GalR1 through GalR3. Over the past decade, some of the receptor subtype-specific effects have been elucidated through pharmacological studies using subtype selective ligands, as well as through molecular approaches involving knockout animals. In this chapter, we summarize the current data which constitute the basis of targeting GalR1, GalR2, and GalR3 for the treatment of various human diseases and pathological conditions, including seizure, Alzheimer's disease, mood disorders, anxiety, alcohol intake in addiction, metabolic diseases, pain and solid tumors.
Collapse
Affiliation(s)
- K Mitsukawa
- Molecular and Integrative Neurosciences Department, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
| | | | | |
Collapse
|
36
|
Galanin, galanin receptor subtypes and depression-like behaviour. EXPERIENTIA SUPPLEMENTUM (2012) 2010; 102:163-81. [PMID: 21299068 DOI: 10.1007/978-3-0346-0228-0_12] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The pathophysiology of depression remains unclear, but involves disturbances in brain monoaminergic transmission. Current antidepressant drugs, which act by enhancing this type of neurotransmission, have limited therapeutic efficacy in a number of patients, and also cause serious side-effects, which limits their compliance. Increasing evidence suggests that neuropeptides, including galanin, can be of relevance in mood disorders. Galanin is co-expressed with and modulates noradrenaline and serotonin transmission, both implicated in depression. Pharmacological and genetic studies suggest a role for galanin in depression-like behaviour in rodents, involving specific receptor subtypes. Thus, stimulation of GalR1 and/or GalR3 receptors results in depression-like phenotype, while activation of the GalR2 receptor reduces depression-like behaviour in the rat. These findings suggest that galanin receptor subtypes may represent novel targets for the development of antidepressant drugs.
Collapse
|
37
|
Galanin impairs cognitive abilities in rodents: relevance to Alzheimer's disease. EXPERIENTIA SUPPLEMENTUM (2012) 2010; 102:133-41. [PMID: 21299066 DOI: 10.1007/978-3-0346-0228-0_10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The neuropeptide galanin and its receptors are localized in brain pathways that mediate learning and memory. Central microinjection of galanin impairs performance of a variety of cognitive tasks in rats. Transgenic mice overexpressing galanin display deficits in some learning and memory tests. The inhibitory role of galanin in cognitive processes, taken together with the fact that overexpression of galanin occurs in Alzheimer's disease, suggests that galanin antagonists may offer a novel therapeutic approach to treat memory loss in patients suffering from Alzheimer's.
Collapse
|
38
|
Ogren SO, Kuteeva E, Elvander-Tottie E, Hökfelt T. Neuropeptides in learning and memory processes with focus on galanin. Eur J Pharmacol 2009; 626:9-17. [PMID: 19837050 DOI: 10.1016/j.ejphar.2009.09.070] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2009] [Revised: 08/27/2009] [Accepted: 09/10/2009] [Indexed: 10/20/2022]
Abstract
Neuropeptides represent by far the most common signalling molecules in the central nervous system. They are involved in a wide range of physiological functions and can act as neurotransmitters, neuromodulators or hormones in the central nervous system and in the periphery. Accumulating evidence during the past 40 years has implicated a number of neuropeptides in various cognitive functions including learning and memory. A major focus has been on the possibility that neuropeptides, by coexisting with classical neurotransmitters, can modulate classical transmitter function of importance for cognition. It has become increasingly clear that most transmitter systems in the brain can release a cocktail of signalling molecules including classical transmitters and several neuropeptides. However, the neuropeptides seem to come into action mainly under conditions of severe stress or aversive events, which have linked their action also to regulation of affective components of behaviour. This paper summarises some of the results of three neuropeptides, which can impact on hippocampal cognition by intrinsic (dynorphins, nociceptin) or extrinsic (galanin) modulation. The results obtained with these neuropeptides in rodent studies indicate that they are important for various aspects of hippocampal learning and memory as well as hippocampal plasticity. Recent studies in humans have also shown that dysregulation of these neuropeptides may be of importance for both neurodegenerative and neuropsychiatric disorders associated with cognitive impairments. It is concluded that compounds acting on neuropeptide receptor subtypes will represent novel targets for a number of disorders, which involve cognitive deficiencies.
Collapse
Affiliation(s)
- Sven Ove Ogren
- Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden.
| | | | | | | |
Collapse
|
39
|
Paschos KA, Veletza S, Chatzaki E. Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression. CNS Drugs 2009; 23:755-72. [PMID: 19689166 DOI: 10.2165/11310830-000000000-00000] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Among the most prevalent of mental illnesses, depression is increasing in incidence in the Western world. It presents with a wide variety of symptoms that involve both the CNS and the periphery. Multiple pharmacological observations led to the development of the monoamine theory as a biological basis for depression, according to which diminished neurotransmission within the CNS, including that of the dopamine, noradrenaline (norepinephrine) and serotonin systems, is the leading cause of the disorder. Current conventional pharmacological antidepressant therapies, using selective monoamine reuptake inhibitors, tricyclic antidepressants and monoamine oxidase inhibitors, aim to enhance monoaminergic neurotransmission. However, the use of these agents presents severe disadvantages, including a delay in the alleviation of depressive symptoms, significant adverse effects and high frequencies of non-responding patients. Neuroendocrinological data of recent decades reveal that depression and anxiety disorders may occur simultaneously due to hypothalamus-pituitary-adrenal (HPA) axis hyperactivity. As a result, the stress-diathesis model was developed, which attempts to associate genetic and environmental influences in the aetiology of depression. The amygdala and the hippocampus control the activity of the HPA axis in a counter-balancing way, and a plethora of regulatory neuropeptide signalling pathways are involved. Intervention at these molecular targets may lead to alternative antidepressant therapeutic solutions that are expected to overcome the limitations of existing antidepressants. This prospect is based on preclinical evidence from pharmacological and genetic modifications of the action of neuropeptides such as corticotropin-releasing factor, substance P, galanin, vasopressin and neuropeptide Y. The recent synthesis of orally potent non-peptide micromolecules that can selectively bind to various neuropeptide receptors permits the onset of clinical trials to evaluate their efficacy against depression.
Collapse
Affiliation(s)
- Konstantinos A Paschos
- Laboratory of Pharmacology, School of Medicine, Democritus University of Thrace (DUTH), Alexandroupolis 68100, Thrace, Greece
| | | | | |
Collapse
|
40
|
Picciotto MR, Brabant C, Einstein EB, Kamens HM, Neugebauer NM. Effects of galanin on monoaminergic systems and HPA axis: Potential mechanisms underlying the effects of galanin on addiction- and stress-related behaviors. Brain Res 2009; 1314:206-18. [PMID: 19699187 DOI: 10.1016/j.brainres.2009.08.033] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2009] [Revised: 08/06/2009] [Accepted: 08/09/2009] [Indexed: 12/20/2022]
Abstract
Like a number of neuropeptides, galanin can alter neural activity in brain areas that are important for both stress-related behaviors and responses to drugs of abuse. Accordingly, drugs that target galanin receptors can alter behavioral responses to drugs of abuse and can modulate stress-related behaviors. Stress and drug-related behaviors are interrelated: stress can promote drug-seeking, and drug exposure and withdrawal can increase activity in brain circuits involved in the stress response. We review here what is known about the ability of galanin and galanin receptors to alter neuronal activity, and we discuss potential mechanisms that may underlie the effects of galanin on behaviors involved in responses to stress and addictive drugs. Understanding the mechanisms underlying galanin's effects on neuronal function in brain regions related to stress and addiction may be useful in developing novel therapeutics for the treatment of stress- and addiction-related disorders.
Collapse
Affiliation(s)
- Marina R Picciotto
- Division of Molecular Psychiatry, Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, Yale University School of Medicine, New Haven, CT, USA.
| | | | | | | | | |
Collapse
|
41
|
Runesson J, Saar I, Lundström L, Järv J, Langel U. A novel GalR2-specific peptide agonist. Neuropeptides 2009; 43:187-92. [PMID: 19467704 DOI: 10.1016/j.npep.2009.04.004] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2008] [Revised: 03/16/2009] [Accepted: 04/17/2009] [Indexed: 01/08/2023]
Abstract
The galanin peptide family and its three receptors have with compelling evidence been implicated in several high-order physiological disorders. The co-localization with other neuromodulators and the distinct up-regulation during and after pathological disturbances has drawn attention to this neuropeptide family. In the current study we present data on receptor binding and functional response for a novel galanin receptor type 2 (GalR2) selective chimeric peptide, M1145 [(RG)(2)-N-galanin(2-13)-VL-(P)(3)-(AL)(2)-A-amide]. The M1145 peptide shows more than 90-fold higher affinity for GalR2 over GalR1 and a 76-fold higher affinity over GalR3. Furthermore, the peptide yields an agonistic effect in vitro, seen as an increase in inositol phosphate (IP) accumulation, both in the absence or the presence of galanin. The peptide design with a N-terminal extension of galanin(2-13), prevails new insights in the assembly of novel subtype specific ligands for the galanin receptor family and opens new possibilities to apply the galanin system as a putative drug target.
Collapse
Affiliation(s)
- Johan Runesson
- Department of Neurochemistry, Stockholm University, Svante Arrheniusv. 21A, SE-10691 Stockholm, Sweden.
| | | | | | | | | |
Collapse
|
42
|
Mitsukawa K, Lu X, Bartfai T. Bidirectional regulation of stress responses by galanin in mice: involvement of galanin receptor subtype 1. Neuroscience 2009; 160:837-46. [PMID: 19272414 DOI: 10.1016/j.neuroscience.2009.02.063] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2008] [Revised: 02/24/2009] [Accepted: 02/27/2009] [Indexed: 02/08/2023]
Abstract
The neuropeptide galanin has been shown to play a role in psychiatric disorders as well as in other biological processes including regulation of pain threshold through interactions with three G-protein coupled receptors, galanin receptor subtypes 1-3 (GalR1-3). While most of the pharmacological studies on galanin in stress-related disorders have been done with rats, the continuous development of genetically engineered mice involving galanin or its receptor subtype(s) validates the importance of mouse pharmacological studies. The present study on mice examined the homeostatic, endocrinological and neuroanatomical effects of the galanin, injected intracerebroventricularly (i.c.v.), in regulation of stress responses after restraint stress. Furthermore, the roles of GalR1 on these effects were studied using GalR1 knockout (KO) mice. The core body temperature and the locomotor activity were monitored with radio telemetry devices. Galanin (i.c.v.) decreased locomotor activity and exerted a bidirectional effect on the restraint stress-induced hyperthermia; a high dose of galanin significantly attenuated the stress-induced hyperthermic response, while a low dose of galanin moderately enhanced this response. The bidirectional effect of galanin was correlated with changes in stress hormone levels (adrenocorticotropic hormone and corticosterone). To neuroanatomically localize the effects of galanin on stress response, cFos immunoreactivity was assessed in galanin receptor rich areas; paraventricular nucleus (PVN) of the hypothalamus and the locus coeruleus (LC), respectively. A high dose of galanin significantly induced cFos activity in the LC but not in the PVN. In GalR1KO mice, a high dose of galanin failed to induce any of the above effects, suggesting the pivotal role of GalR1 in decreased locomotor activity and stress-resistant effects caused by galanin i.c.v. injection studied here.
Collapse
Affiliation(s)
- K Mitsukawa
- Molecular and Integrative Neurosciences Department, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
| | | | | |
Collapse
|
43
|
Kuteeva E, Wardi T, Lundström L, Sollenberg U, Langel U, Hökfelt T, Ogren SO. Differential role of galanin receptors in the regulation of depression-like behavior and monoamine/stress-related genes at the cell body level. Neuropsychopharmacology 2008; 33:2573-85. [PMID: 18172432 DOI: 10.1038/sj.npp.1301660] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The present study on rat examined the role of galanin receptor subtypes in regulation of depression-like behavior as well as potential molecular mechanisms involved in the locus coeruleus (LC) and dorsal raphe (DR). The effect of intracerebroventricular (i.c.v.) infusion of galanin or galanin receptor GalR1- and GalR2-selective ligands was studied in the forced swim test, followed by quantitative in situ hybridization studies. Naive control, non-treated (swim control), saline- and fluoxetine-treated rats were used as controls in the behavioral and in situ hybridization studies. Subchronic treatment with fluoxetine reduced immobility and climbing time. Intracerebroventricular infusion of galanin, the GalR1 agonist M617 or the GalR2 antagonist M871 increased, while the GalR2(R3) agonist AR-M1896 decreased, immobility time compared to the aCSF-treated animals. Galanin also decreased the time of climbing. Galanin mRNA levels were upregulated by the combination of injection+swim stress in the saline- and the fluoxetine-treated groups in the LC, but not in the DR. Also tyrosine hydroxylase levels in the LC were increased following injection+swim stress in the saline- and fluoxetine-treated rats. Tryptophan hydroxylase 2 and serotonin transporter mRNAs were not significantly affected by any treatment. 5-HT(1A) mRNA levels were downregulated following i.c.v. galanin, M617 or AR-M1896 infusion. These results indicate a differential role of galanin receptor subtypes in depression-like behavior in rodents: GalR1 subtype may mediate 'prodepressive' and GalR2 'antidepressant' effects of galanin. Galanin has a role in behavioral adaptation to stressful events involving changes of molecules important for noradrenaline and/or serotonin transmission.
Collapse
Affiliation(s)
- Eugenia Kuteeva
- Department of Neuroscience, Karolinska Institutet, Retzius vag 8, Stockholm S-171 77 [corrected] Sweden.
| | | | | | | | | | | | | |
Collapse
|
44
|
Fuxe K, Marcellino D, Rivera A, Diaz-Cabiale Z, Filip M, Gago B, Roberts D, Langel U, Genedani S, Ferraro L, de la Calle A, Narvaez J, Tanganelli S, Woods A, Agnati L. Receptor–receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. ACTA ACUST UNITED AC 2008; 58:415-52. [DOI: 10.1016/j.brainresrev.2007.11.007] [Citation(s) in RCA: 167] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2007] [Revised: 11/26/2007] [Accepted: 11/29/2007] [Indexed: 01/01/2023]
|
45
|
Abstract
The neuropeptide galanin and its receptors are localized in brain pathways mediating learning and memory. Central microinjection of galanin impairs performance of a variety of cognitive tasks in rats. Transgenic mice overexpressing galanin display deficits in some learning and memory tests. The inhibitory role of galanin in cognitive processes, taken together with the overexpression of galanin in Alzheimer's disease, suggests that galanin antagonists may offer a novel therapeutic approach to treat memory loss in Alzheimer's patients.
Collapse
Affiliation(s)
- J N Crawley
- Laboratory of Behavioral Neuroscience, National Institute of Mental Health, Porter Neuroscience Research, Center Building 35, Room 1C-903, Mail Code 3730, Bethesda, Maryland 20892-3730, USA.
| |
Collapse
|
46
|
Unschuld PG, Ising M, Erhardt A, Lucae S, Kohli M, Kloiber S, Salyakina D, Thoeringer CK, Kern N, Lieb R, Uhr M, Binder EB, Müller-Myhsok B, Holsboer F, Keck ME. Polymorphisms in the galanin gene are associated with symptom-severity in female patients suffering from panic disorder. J Affect Disord 2008; 105:177-84. [PMID: 17573119 DOI: 10.1016/j.jad.2007.05.006] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/10/2007] [Revised: 05/08/2007] [Accepted: 05/09/2007] [Indexed: 11/25/2022]
Abstract
BACKGROUND Galanin (GAL) is a neuropeptide, which is expressed primarily in limbic nuclei in the brain and mediates miscellaneous physiological processes and behaviors. In animal studies, both the application of GAL and antagonism of its receptors have been shown to affect anxiety-like and depression-related behavior. In humans, intravenous administration of the neuropeptide galanin has been reported to have fast antidepressant efficacy. Furthermore, GAL is involved in hypothalamic-hypophysiotropic signalling and cosecreted with luteinizing hormone-releasing hormone (LHRH), possibly acting as a mediator of estrogen action. METHODS In this study six single nucleotide polymorphisms (SNPs) within the gene coding for GAL were analyzed for possible associations with diagnosis and severity of symptoms in 121 male and female patients suffering from panic disorder (PD). RESULTS Our results suggest an association between genetic variations in the GAL-gene and severity of PD-symptoms in female patients. The most pronounced effects could be observed for two haplotypes containing the closely linked, non-protein-coding SNPs rs948854 and rs4432027. Both polymorphisms are located within CpG-dinucleotides in the promoter region of GAL and thus might be involved in epigenetic regulation of the GAL-gene. LIMITATIONS A relatively small patient sample was analyzed in this study, the herein presented results need to be validated in independent studies. CONCLUSIONS The results of this study underline the potential of further genetic research concerning GAL and a possible role of this neuropeptide in the pathogenesis of female PD. In this regard, GAL and its receptors appear to be a promising target for pharmacological therapy of anxiety and affective disorders.
Collapse
Affiliation(s)
- Paul G Unschuld
- Max Planck Institute of Psychiatry, Kraepelinstr. 2-10, 80804 München, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Lundström L, Sollenberg UE, Bartfai T, Langel Ü. Molecular characterization of the ligand binding site of the human galanin receptor type 2, identifying subtype selective interactions. J Neurochem 2007; 103:1774-84. [DOI: 10.1111/j.1471-4159.2007.04959.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
48
|
Rajarao SJR, Platt B, Sukoff SJ, Lin Q, Bender CN, Nieuwenhuijsen BW, Ring RH, Schechter LE, Rosenzweig-Lipson S, Beyer CE. Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon. Neuropeptides 2007; 41:307-20. [PMID: 17637475 DOI: 10.1016/j.npep.2007.05.001] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2007] [Revised: 05/09/2007] [Accepted: 05/10/2007] [Indexed: 01/22/2023]
Abstract
Galanin's influence on monoaminergic neurotransmission, together with its discrete CNS distribution in corticolimbic brain areas, points to a potential role for this neuropeptide in mediating anxiety- and depression-like responses. To evaluate this hypothesis, the non-selective galanin receptor agonist, galnon, was tested in multiple preclinical models of anxiolytic- and antidepressive-like activity. Acute administration of galnon (0.03-1mg/kg, i.p.) dose-dependently increased punished crossings in the four plate test, with magnitude similar to the effects of the endogenous ligand, galanin (0.1-1.0 microg, i.c.v.). Moreover, the effects of galnon and galanin were blocked by central administration of the non-selective galanin receptor antagonist, M35 (10 microg, i.c.v.). Interestingly, the benzodiazepine receptor antagonist, flumazenil (1mg/kg, i.p.), reversed galnon's effect in the four plate test, implicating GABAergic neurotransmission as a potential mechanism underlying this anxiolytic-like response. In the elevated zero maze, galnon (0.3-3.0mg/kg, i.p.) and galanin (0.03-0.3 microg, i.c.v.) increased the time spent in the open arms, while in the stress-induced hyperthermia model, galnon (0.3-30 mg/kg, i.p.) attenuated stress-induced changes in body temperature. Consistent with these anxiolytic-like effects, in vivo microdialysis showed that acute galnon (3mg/kg, i.p.) treatment preferentially elevated levels of GABA in the rat amygdala, a brain area linked to fear and anxiety behaviors. In contrast to the effects in anxiety models, neither galnon (1-5.6 mg/kg, i.p.) nor galanin (0.3-3.0 microg, i.c.v.) demonstrated antidepressant-like effects in the mouse tail suspension test. Galnon (1-10mg/kg, i.p.) also failed to reduce immobility time in the rat forced swim test. In vitro, galnon and galanin showed affinity for human galanin receptors expressed in Bowes melanoma cells (K(i)=5.5 microM and 0.2 nM, respectively). Galanin displayed high affinity and functional potency for membranes expressing rat GALR1 receptors (K(i)=0.85 nM; EC(50)=0.6 nM), while galnon (10 microM) failed to displace radiolabeled galanin or inhibit cAMP production in the same GALR1 cell line. Galnon (10 microM) showed affinity for NPY1, NK2, M5, and somatostatin receptors but no affinity for galanin receptors expressed in rat hippocampal membranes. Taken together, the present series of studies demonstrate novel effects of galnon in various preclinical models of anxiety and highlight the galaninergic system as a novel therapeutic target for the treatment of anxiety-related disorders. Moreover, these data indicate rodent GALR1 receptors do not mediate galnon's in vivo activity.
Collapse
Affiliation(s)
- S Johannes R Rajarao
- Depression and Anxiety Research, Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Zorrilla E, Brennan M, Sabino V, Lu X, Bartfai T. Galanin type 1 receptor knockout mice show altered responses to high-fat diet and glucose challenge. Physiol Behav 2007; 91:479-85. [PMID: 17223141 PMCID: PMC2080849 DOI: 10.1016/j.physbeh.2006.11.011] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2006] [Revised: 11/16/2006] [Accepted: 11/20/2006] [Indexed: 11/25/2022]
Abstract
Galanin, a brain and pancreatic peptide with three receptor subtypes (GALR1, GALR2, and GALR3), is hypothesized to participate in energy homeostasis and glucoregulation. Hypothalamic galanin expression is induced by dietary fat, and intra-hypothalamic galanin administration has orexigenic/anabolic properties. Systemic galanin infusion alters glucoregulation in non-human species, partly through direct actions on pancreatic islets. However, the physiologic significance of endogenous galanin-GALR signaling is unclear. The present studies tested the hypotheses that GALR1 deficiency alters food intake and feed efficiency following switches to high-fat diet and that GALR1 deficiency alters whole-body glucose homeostasis. Adult, male GALR1 knockout (-/-), heterozygote (+/-), and C57BL/6J control (+/+) mice were studied. GALR1 deficiency impaired adaptation to a 3-day high-fat diet challenge, leading to increased food intake, feed efficiency and weight gain. However, during the following 2 weeks, GALR1 knockout mice decreased intake, consuming less daily energy than while maintained on low-fat diet and also than heterozygote littermates. Chow-maintained GALR1 knockout mice showed relative hyperglycemia in fed and d-glucose (i.p. 1.5 g/kg)-challenged states. GALR1 knockout mice showed normal food intake, feed efficiency and weight accrual on low-fat diets, normal fasted glucose levels, and normal glucose sensitivity to porcine insulin (i.p. 1 IU/kg) in vivo. The results support the hypotheses that galanin-GALR1 systems help adapt food intake and metabolism to changes in dietary fat and modulate glucose disposition in mice.
Collapse
Affiliation(s)
- E.P. Zorrilla
- The Harold L. Dorris Neurological Research Center, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA
- Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA
- Correspondence and requests for materials should be addressed to: Eric P. Zorrilla () or Tamas Bartfai (), Mail Code: SP300-2400 (EPZ) or SR-307 (TB), The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037 USA, Phone: 858-784-7416 (EPZ) or 858-784-8404 (TB), Fax: 858-784-7405 (EPZ) or 858-784-9099 (TB)
| | - M. Brennan
- The Harold L. Dorris Neurological Research Center, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA
- Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA
| | - V. Sabino
- The Harold L. Dorris Neurological Research Center, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA
- Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA
| | - X. Lu
- The Harold L. Dorris Neurological Research Center, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA
- Molecular and Integrative Neuroscience Department (MIND), The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA
| | - T. Bartfai
- The Harold L. Dorris Neurological Research Center, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA
- Molecular and Integrative Neuroscience Department (MIND), The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA
- Correspondence and requests for materials should be addressed to: Eric P. Zorrilla () or Tamas Bartfai (), Mail Code: SP300-2400 (EPZ) or SR-307 (TB), The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037 USA, Phone: 858-784-7416 (EPZ) or 858-784-8404 (TB), Fax: 858-784-7405 (EPZ) or 858-784-9099 (TB)
| |
Collapse
|
50
|
Bailey KR, Pavlova MN, Rohde AD, Hohmann JG, Crawley JN. Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze. Pharmacol Biochem Behav 2007; 86:8-20. [PMID: 17257664 PMCID: PMC1853242 DOI: 10.1016/j.pbb.2006.11.024] [Citation(s) in RCA: 89] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2006] [Revised: 11/14/2006] [Accepted: 11/20/2006] [Indexed: 01/31/2023]
Abstract
The neuropeptide galanin has been implicated in anxiety-related behaviors, cognition, analgesia, and feeding in rodents. Neuromodulatory actions of galanin are mediated by three G-protein coupled receptors, GalR1, GalR2, and GalR3. The present study investigates the role of the GalR2 receptor by evaluating behavioral phenotypes of mice with a targeted mutation in the GalR2 gene. A three-tiered behavioral phenotyping approach first examined control measures of general health, body weight, neurological reflexes, sensory abilities and motor function. Mice were then assessed on several tests for cognitive and anxiety-like behaviors. GalR2 null mutants and heterozygotes were not significantly different from wildtype littermates on two cognitive tests previously shown to be sensitive to galanin manipulation: acquisition of the Morris water maze spatial task, and trace cued and contextual fear conditioning, an emotional learning and memory task. Two independent cohorts of GalR2 null mutant mice demonstrated an anxiogenic-like phenotype in the elevated plus-maze. No genotype differences were detected on several other measures of anxiety-like behavior. The discovery of an anxiogenic phenotype specific to the elevated plus-maze, similar to findings in GalR1 null mutants, highlights the potential therapeutic efficacy of targeting GalR1 and GalR2 receptors in treating anxiety disorders.
Collapse
|